These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 33279523)

  • 1. Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B.
    Tout I; Lampertico P; Berg T; Asselah T
    Antiviral Res; 2021 Jan; 185():104992. PubMed ID: 33279523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
    Rinker F; Zimmer CL; Höner Zu Siederdissen C; Manns MP; Kraft ARM; Wedemeyer H; Björkström NK; Cornberg M
    J Hepatol; 2018 Sep; 69(3):584-593. PubMed ID: 29758333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When can we stop nucleoside analogues in patients with chronic hepatitis B?
    Chong CH; Lim SG
    Liver Int; 2017 Jan; 37 Suppl 1():52-58. PubMed ID: 28052620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes.
    Van Hees S; Bourgeois S; Van Vlierberghe H; Sersté T; Francque S; Michielsen P; Sprengers D; Reynaert H; Henrion J; Negrin Dastis S; Delwaide J; Lasser L; Decaestecker J; Orlent H; Janssens F; Robaeys G; Colle I; Stärkel P; Moreno C; Nevens F; Vanwolleghem T;
    Aliment Pharmacol Ther; 2018 Apr; 47(8):1170-1180. PubMed ID: 29498078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?
    Moreno-Cubero E; Del Arco RTS; Peña-Asensio J; de Villalobos ES; Míquel J; Larrubia JR
    World J Gastroenterol; 2018 May; 24(17):1825-1838. PubMed ID: 29740199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients.
    Kao JH; Jeng WJ; Ning Q; Su TH; Tseng TC; Ueno Y; Yuen MF
    Hepatol Int; 2021 Aug; 15(4):833-851. PubMed ID: 34297329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg-Negative Chronic Hepatitis B.
    van Bömmel F; Berg T
    Hepatol Commun; 2021 Oct; 5(10):1632-1648. PubMed ID: 34558833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can we stop nucleoside analogues before HBsAg loss?
    Papatheodoridi M; Papatheodoridis G
    J Viral Hepat; 2019 Aug; 26(8):936-941. PubMed ID: 30803099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative.
    He D; Guo S; Chen W; Chen X; Yan G; Wang J; Li M; Zhu P; Huang H; Wang Y
    BMC Infect Dis; 2013 Oct; 13():458. PubMed ID: 24090287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study).
    Hirode G; Choi HSJ; Chen CH; Su TH; Seto WK; Van Hees S; Papatheodoridi M; Lens S; Wong G; Brakenhoff SM; Chien RN; Feld J; Sonneveld MJ; Chan HLY; Forns X; Papatheodoridis GV; Vanwolleghem T; Yuen MF; Hsu YC; Kao JH; Cornberg M; Hansen BE; Jeng WJ; Janssen HLA;
    Gastroenterology; 2022 Mar; 162(3):757-771.e4. PubMed ID: 34762906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients.
    García-López M; Lens S; Pallett LJ; Testoni B; Rodríguez-Tajes S; Mariño Z; Bartres C; García-Pras E; Leonel T; Perpiñán E; Lozano JJ; Rodríguez-Frías F; Koutsoudakis G; Zoulim F; Maini MK; Forns X; Pérez-Del-Pulgar S
    J Hepatol; 2021 May; 74(5):1064-1074. PubMed ID: 33278456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B.
    van Bömmel F; Berg T
    Liver Int; 2018 Feb; 38 Suppl 1():90-96. PubMed ID: 29427489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
    Viganò M; Mangia G; Lampertico P
    Liver Int; 2014 Feb; 34 Suppl 1():120-6. PubMed ID: 24373088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Better Antiviral Efficacy Found in Nucleos(t)ide Analog (NA) Combinations with Interferon Therapy than NA Monotherapy for HBeAg Positive Chronic Hepatitis B: A Meta-Analysis.
    Wei W; Wu Q; Zhou J; Kong Y; You H
    Int J Environ Res Public Health; 2015 Aug; 12(8):10039-55. PubMed ID: 26308024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa?
    Vlachogiannakos J; Papatheodoridis GV
    Liver Int; 2014 Feb; 34 Suppl 1():127-32. PubMed ID: 24373089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 48 weeks outcome after cessation of nucleos(t)ide analogue therapy in chronic hepatitis B patients.
    Gao L; Hu Y; Shi X; Li X; Zhang D; Ren H
    Ann Hepatol; 2020; 19(3):329-334. PubMed ID: 31884016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg-Negative CHB.
    Wübbolding M; Lopez Alfonso JC; Lin CY; Binder S; Falk C; Debarry J; Gineste P; Kraft ARM; Chien RN; Maasoumy B; Wedemeyer H; Jeng WJ; Meyer Hermann M; Cornberg M; Höner Zu Siederdissen C
    Hepatol Commun; 2021 Jan; 5(1):97-111. PubMed ID: 33437904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B.
    Fan R; Peng J; Xie Q; Tan D; Xu M; Niu J; Wang H; Ren H; Chen X; Wang M; Sheng J; Tang H; Bai X; Wu Y; Zhou B; Sun J; Hou J;
    J Infect Dis; 2020 Jul; 222(4):611-618. PubMed ID: 32211776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study).
    Liem KS; Fung S; Wong DK; Yim C; Noureldin S; Chen J; Feld JJ; Hansen BE; Janssen HLA
    Gut; 2019 Dec; 68(12):2206-2213. PubMed ID: 31462554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current practice and contrasting views on discontinuation of nucleos(t)ide analog therapy in chronic hepatitis B.
    Hadziyannis E; Hadziyannis S
    Expert Rev Gastroenterol Hepatol; 2020 Apr; 14(4):243-251. PubMed ID: 32162562
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.